{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:55:02Z","timestamp":1774421702000,"version":"3.50.1"},"reference-count":41,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"8","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2021,7,27]]},"DOI":"10.1167\/tvst.10.8.23","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:34:23Z","timestamp":1627403663000},"page":"23","source":"Crossref","is-referenced-by-count":6,"title":["Automated Retinal Layer Segmentation in <i>CLN2<\/i>-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy"],"prefix":"10.1167","volume":"10","author":[{"given":"Kyle D.","family":"Kovacs","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Orlin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolan","family":"Sondhi","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Kaminsky","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald J.","family":"D'Amico","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szil\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retina Service, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/(ISSN)1096-8628","article-title":"Neuronal ceroid-lipofuscinoses in Italy: an epidemiological study","volume":"57","author":"Cardona","year":"1995","journal-title":"Am J Med Genet"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1469-8749.1974.tb04183.x","article-title":"Infantile type of so-called neuronal ceroid-lipofuscinosis","volume":"16","author":"Santavuori","year":"1974","journal-title":"Dev Med Child Neurol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","article-title":"The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland","volume":"74","author":"Moore","year":"2008","journal-title":"Clin Genet"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management Strategies for CLN2 Disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"2","key":"bib5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","article-title":"New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses","volume":"79","author":"Williams","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"bib6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlsch\u00fctter","year":"2019","journal-title":"CNS Drugs"},{"issue":"10 Pt B","key":"bib8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","article-title":"Genetics of the neuronal ceroid lipofuscinoses (Batten disease)","volume":"1852","author":"Mole","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0167-4838(98)00238-6","article-title":"Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis","volume":"1429","author":"Rawlings","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0014-5793(98)01683-4","article-title":"Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I","volume":"443","author":"Vines","year":"1999","journal-title":"FEBS Lett"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/(ISSN)1096-8628","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am J Med Genet"},{"issue":"5","key":"bib13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/humu.22292","article-title":"Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease)","volume":"34","author":"Sun","year":"2013","journal-title":"Hum Mutat"},{"issue":"1","key":"bib14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","article-title":". Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America","volume":"516","author":"Kohan","year":"2013","journal-title":"Gene"},{"issue":"20","key":"bib15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"bib17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jnr.v92.11","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J Neurosci Res"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"8","key":"bib21","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","article-title":"Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function","volume":"8","author":"Orlin","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"bib22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.oret.2020.01.011","article-title":"Symmetric age-association of retinal degeneration in patients with CLN2-associated Batten disease","volume":"4","author":"Kovacs","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ymgme.2004.06.019","article-title":"Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease)","volume":"83","author":"Weleber","year":"2004","journal-title":"Mol Genet Metab"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/bjo.2006.091637","article-title":"Batten disease: features to facilitate early diagnosis","volume":"90","author":"Collins","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/13816810903258829","article-title":"Autofluorescence and infrared retinal imaging in patients and obligate carriers with neuronal ceroid lipofuscinosis","volume":"30","author":"Kelly","year":"2009","journal-title":"Ophthal Genet"},{"issue":"Pt 3b","key":"bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/eye.1998.148","article-title":"The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses","volume":"12","author":"Weleber","year":"1998","journal-title":"Eye (Lond)"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/IAE.0b013e31819b0542","article-title":"Funduscopic and angiographic appearance in the neuronal ceroid lipofuscinoses","volume":"29","author":"Hainsworth","year":"2009","journal-title":"Retina"},{"key":"bib28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/OPTH.S14257","article-title":"Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the \u201cflying saucer\u201d sign)","volume":"4","author":"Chen","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"bib29","doi-asserted-by":"crossref","DOI":"10.1097\/ICB.0000000000000993","article-title":"Topographic optical coherence tomography segmentation shows limited ellipsoid zone recovery in mild hydroxychloroquine retinopathy","author":"de Sisternes","year":"2020 Mar 5","journal-title":"Retin Cases Brief Rep"},{"issue":"3","key":"bib30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/2474126419836067","article-title":"Automated segmentation measurements of the outer nuclear layer in determining cases of hydroxychloroquine toxicity: a retrospective study","volume":"3","author":"Jain","year":"2019","journal-title":"J Vitreoret Dis"},{"issue":"10","key":"bib31","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1097\/IAE.0000000000001036","article-title":"Volumetric single-layer inner retinal analysis in patients with hydroxychloroquine toxicity","volume":"36","author":"Modi","year":"2016","journal-title":"Retina"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-016-0042-y","article-title":"Expanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation","volume":"2","author":"Lally","year":"2016","journal-title":"Int J Retina Vitreous"},{"issue":"3","key":"bib33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/IAE.0000000000002408","article-title":"Sequential changes in hydroxychloroquine retinopathy up to 20 years after stopping the drug: implications for mild versus severe toxicity","volume":"39","author":"Pham","year":"2019","journal-title":"Retina"},{"issue":"3","key":"bib34","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1167\/iovs.10-5946","article-title":"Revealing Henle's fiber layer using spectral domain optical coherence tomography","volume":"52","author":"Lujan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ajo.2015.06.032","article-title":"Multimodal imaging of central retinal disease progression in a 2-year mean follow-up of retinitis pigmentosa","volume":"160","author":"Sujirakul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.1167\/iovs.16-20963","article-title":"Asymmetric inter-eye progression in Stargardt disease","volume":"57","author":"Lambertus","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"572","key":"bib37","doi-asserted-by":"publisher","first-page":"eabb5413","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-Associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Trans Med"},{"issue":"5","key":"bib38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"7","key":"bib39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14712598.2018.1492544","article-title":"Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses","volume":"18","author":"Donsante","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.exer.2014.06.008","article-title":"Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis","volume":"125","author":"Whiting","year":"2014","journal-title":"Exp Eye Res"},{"issue":"8","key":"bib41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"bib7","volume-title":"The neuronal ceroid lipofuscinoses (Batten disease)","author":"Mole","year":"2011","edition":"2 ed."},{"key":"bib11","first-page":"37","article-title":"Classic late infantile NCL","volume-title":"The neuronal ceroid lipofuscinosis (Batten disease)","author":"Williams","year":"1999."},{"key":"bib16","volume-title":"CADTH Canadian Drug Expert Committee recommendation: cerliponase alfa","author":"CADTH Common Drug Review","year":"2019"},{"key":"bib18","volume-title":"Indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet]","author":"Clinical Review Report: Cerliponase Alfa (Brineura): (Biomarin Pharmaceutical (Canada) Inc.)","year":"2019 Jun"}],"container-title":["Translational Vision Science &amp; Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:34:32Z","timestamp":1627403672000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2776513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.10.8.23","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,27]]}}}